Coventry, UK, 6th June 2017 / Medherant Ltd, a University of Warwick spin-out company developing a novel transdermal drug delivery patch technology, is pleased to announce the appointment of Sheryl Caswell as Head of Clinical Development. Sheryl joins Medherant as the Company prepares to start clinical studies with its first product, an ibuprofen patch developed using its TEPI Patch® technology.
Nigel Davis, CEO, commented, “We’re delighted that Sheryl will be joining us at such an important time in the Company’s development. Sheryl has over 20 years’ experience leading clinical development programmes on a wide range of products including other ibuprofen products”.
Medherant’s next-generation drug delivery platform, TEPI Patch®, is designed to address many of the disadvantages of previous transdermal drug delivery patches. It will enable a wider range of drugs to be delivered through the skin, including those that are unsuitable for oral administration, and improve the user experience. Medherant is initially using the technology to develop products for pain relief, the first of which will be an ibuprofen patch. The technology will enable controlled release of drugs for up to at least 24 hours.
Sheryl commented, “I am delighted to join Medherant to lead clinical development at this exciting time and look forward to initiation of the Company’s first clinical study. I believe the TEPI Patch® technology developed by Medherant will provide patients with a much-needed convenient dosing form for a wide range of drugs.”
Nicola Broughton, Head of Universities at Mercia Technologies PLC, which invested in Medherant last year, said, “Sheryl will be a great asset to the Medherant team, bringing a wealth of experience as the Company takes its next important step into clinical development. The technology is incredibly versatile and we are excited about Medherant developing a range of products to deliver drugs through the skin.”
For further information, contact:
Nigel Davis, CEO
T: +44 (0)24 7632 3060
Media Relations, Sciad Communications
Deborah Cockerill, Managing Partner
T: +44 (0)20 7470 8801
Notes for Editors
Medherant Ltd is a leading developer of next-generation transdermal drug delivery patches. The Company was founded by Professor David Haddleton and the University of Warwick in 2015.
Medherant has built upon its founders’ world-leading expertise in bio-adhesives and polymer chemistry to create adhesive drug delivery patches that overcome many of the limitations of patches currently on the market:
- Its TEPI Patch® technology can be used with a wider range of drugs, including those that are not suitable for oral administration.
- The amount of drug that can be loaded into the patch is greater, enabling the development of more effective transdermal therapies.
- The TEPI Patch® contains a novel adhesive which will provide a better patient experience as the patch sticks to the skin for longer, is less painful to remove, and does not leave a mark on the skin.
Medherant is developing products containing proven drugs that it intends to license prior to commercialisation. The Company’s first product is an ibuprofen patch. Manufacture for clinical trials will take place at AdhexPharma in France in the second half of 2017.
Medherant also runs feasibility studies that give companies the opportunity to see the benefits of delivering their drugs with TEPI Patch® technology. Medherant seeks partnerships with companies wishing to extend the commercial life of their products or those that have drugs that cannot be delivered orally at sufficient dosage.
Medherant is backed by Mercia Technologies PLC, a national investment group focused on the creation, funding and scaling of innovative businesses with high growth potential from the UK regions.
For more information, please see www.medherant.co.uk